Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor

Neuropathic pain affects a large proportion of the population and reduces a person’s ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	N. Smith, H. Ismail, N. Schellack
Formato:	article
Lenguaje:	EN
Publicado:	AOSIS 2016
Materias:	melatonin neuropathic pain mt2 receptor opioids nsaids Medicine R
Acceso en línea:	https://doaj.org/article/050c4c36cf34433d875f8f064600d765
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:050c4c36cf34433d875f8f064600d765
record_format	dspace
spelling	oai:doaj.org-article:050c4c36cf34433d875f8f064600d7652021-11-24T07:44:18ZNeuropathic pain: targeting the melatonin MT<sub>2</sub> receptor2078-61902078-620410.4102/safp.v58i4.4528https://doaj.org/article/050c4c36cf34433d875f8f064600d7652016-08-01T00:00:00Zhttps://safpj.co.za/index.php/safpj/article/view/4528https://doaj.org/toc/2078-6190https://doaj.org/toc/2078-6204Neuropathic pain affects a large proportion of the population and reduces a person’s ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with NSAIDS and opioids as first-line therapy. In 2012, a South African guideline on neuropathic pain was released, which stated that opioid therapy should be reserved for last-line treatment only. More recently, melatonin, commonly known as the neurohormone that regulates the circadian rhythm, has come to light as a therapeutic treatment option in the neuropathic pain setting. Early clinical trials showed a link between melatonin and chronic pain, which includes neuropathic pain. The MT2 receptor has also been specifically linked to the control of neuropathic pain and inflammation.N. SmithH. IsmailN. SchellackAOSISarticlemelatoninneuropathic painmt2 receptoropioidsnsaidsMedicineRENSouth African Family Practice, Vol 58, Iss 4, Pp 31-34 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	melatonin neuropathic pain mt2 receptor opioids nsaids Medicine R
spellingShingle	melatonin neuropathic pain mt2 receptor opioids nsaids Medicine R N. Smith H. Ismail N. Schellack Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
description	Neuropathic pain affects a large proportion of the population and reduces a person’s ability to perform optimally. In South Africa, there are a host of factors that hinder the correct diagnosis and treatment of neuropathic pain. Patients suffering from neuropathic pain are treated suboptimally with NSAIDS and opioids as first-line therapy. In 2012, a South African guideline on neuropathic pain was released, which stated that opioid therapy should be reserved for last-line treatment only. More recently, melatonin, commonly known as the neurohormone that regulates the circadian rhythm, has come to light as a therapeutic treatment option in the neuropathic pain setting. Early clinical trials showed a link between melatonin and chronic pain, which includes neuropathic pain. The MT2 receptor has also been specifically linked to the control of neuropathic pain and inflammation.
format	article
author	N. Smith H. Ismail N. Schellack
author_facet	N. Smith H. Ismail N. Schellack
author_sort	N. Smith
title	Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
title_short	Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
title_full	Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
title_fullStr	Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
title_full_unstemmed	Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor
title_sort	neuropathic pain: targeting the melatonin mt<sub>2</sub> receptor
publisher	AOSIS
publishDate	2016
url	https://doaj.org/article/050c4c36cf34433d875f8f064600d765
work_keys_str_mv	AT nsmith neuropathicpaintargetingthemelatoninmtsub2subreceptor AT hismail neuropathicpaintargetingthemelatoninmtsub2subreceptor AT nschellack neuropathicpaintargetingthemelatoninmtsub2subreceptor
_version_	1718415837429235712

Neuropathic pain: targeting the melatonin MT<sub>2</sub> receptor

Ejemplares similares